Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Can you beat 50% per month? -- Ignore unavailable to you. Want to Upgrade?

To: Smiling Bob who wrote (9594)	3/14/2006 9:26:49 AM
From: Smiling Bob	Respond to of 19256

GTHA -.21 ask- had hidden news yesterday - Mad cow play CORRECTING and REPLACING GeneThera Set to Commence Operations in Mexico Monday March 13, 2:08 pm ET WHEAT RIDGE, Colo.--(BUSINESS WIRE)--March 13, 2006--Reissuing release to add ticker symbol for searching purposes. The corrected release reads: GENETHERA SET TO COMMENCE OPERATIONS IN MEXICO In line with its strategic direction to commercialize live animal testing for veterinary diseases on a worldwide basis, GeneThera (OTCBB: GTHA - News) announces a joint venture has been formed with Nutricion Avanzada S.A. de C.V. of Monterrey, Mexico. Nutricion Avanzada is a large private multinational distributor of nutritional supplements for animals with access to large amounts of cattle throughout Mexico. The formation of a new company allows the joint venture usage of GeneThera's proprietary diagnostic solution based on its genetic expression assay, GEA(TM) and access to Nutricion Avanzada's customer base. The company will operate as an approved independent laboratory facility in Monterrey, Mexico, with the purpose of validating and commercializing a live blood test for veterinary diseases. Commenting on the formation of this multinational company, Dr. Tony Milici, CEO of GeneThera, said: "This new company will give us the base of operations needed in Mexico to begin the commercialization process of our live animal test. The Mexican cattle industry is excited about the potential of our live test. Having a live animal test within Mexico will be of paramount importance from a financial standpoint to the live stock industry in Mexico." Sergio I. Gonzalez Gonzalez, principal of Nutricion Avanzada, said: "We couldn't be more thrilled with the formation of this new entity with GeneThera. We look forward to a rewarding and successful period working together and in bringing these tests to Mexico in support of our country's large livestock program." The new company will be equally owned by GeneThera and Nutricion Avanzada. About Genethera, Inc. GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne's Disease, diseases affecting cattle worldwide. "Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital. Contact: GeneThera, Inc. Dr. Tony Milici, 303-463-6371 genethera.net Source: GeneThera, Inc.